Wednesday, October 31, 2012

International Pharmaceutical Bribes: Analysis: U.S. foreign bribery penalties for drugmakers may lack bite | Reuters

International Pharmaceutical Bribes: International Whistleblower Reward Laws Offer Financial Rewards to Pharmaceutical Professionals That Expose International Pharmaceutical Bribes and Illegal Drug Procurement Kickbacks by International Pharmaceutical Bribe Lawyer, Drug Procurement Bribe Lawyer, and Drug Executive Whistleblower Lawyer Jason S. Coomer

International whistleblowers can recover large amounts of money for exposing international pharmaceutical bribes and illegal kickbacks.  As such, pharmaceutical representatives, international drug executives, government officials, physicians, health care providers, community activists, and other persons, who are the original source of specialized knowledge of international pharmaceutical bribes and other illicit payments for drug procurement, medical device procurement, medication, pharmaceutical, and medical equipment contracts.
For more information on a potential International Pharmaceutical Bribe Whistleblower Lawsuits, please feel free to go to the following web pages: International Medicine Bribe Lawyer and International Procurement Bribe Lawyer.

Analysis: U.S. foreign bribery penalties for drugmakers may lack bite | Reuters

"Global drugmakers are paying tens of millions of dollars to settle U.S. allegations that they bribed their way across emerging markets, but harsher penalties may be needed to deter the practice in untapped regions where billions are at stake."

"Federal authorities have cast a wide net to weed out suspected gift-giving and kickbacks to foreign doctors and government officials to gain a foothold in burgeoning new markets in Asia, Eastern Europe and Latin America."

"At least eight of the world's top 10 drugmakers, including Bristol-Myers Squibb Co, Pfizer Inc and Johnson &, have disclosed U.S. probes under the 1977 Foreign Corrupt Practices Act (FCPA).
Pfizer agreed to pay $60 million this year to settle FCPA charges and J&J reached a $70 million settlement last year. Pfizer is on track to record $10 billion in sales from emerging markets this year, while J&J said Brazil, Russia, India and China accounted for just under 10 percent of the $65 billion in sales it reported last year."

"With so much at stake outside of established markets in the United States and Europe, some experts say fines like these are hardly a deterrent."

"The $60 million fine for Pfizer to a lay person sounds like quite a bit of money, but in perspective it took less than two days of Lipitor sales during its peak. It's really just chump change for them," said Michael Leibfried, a senior analyst with market research consulting firm GlobalData. The cholesterol pill at its height was a $13 billion a year cash cow for Pfizer."

No comments:

Post a Comment